NCT00089661COMPLETEDanonymous

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer

Sponsor

Source record

Amgen

Phase

Source record

PHASE3

Modality

AI-normalized

small molecule

Target

AI-normalized

Placebo, AMG 162 / Denosumab

Indication / condition

AI-normalized

Breast Cancer

Intervention

Source record

Placebo, AMG 162 / Denosumab

Related intelligence directories

Indication directory: Breast Cancer Modality directory: small molecule Target directory: Placebo

Source & freshness

Source record

NCT ID

NCT00089661

Original source

ClinicalTrials.gov

Source last updated

Oct 17, 2018

Ingested at

Jun 18, 2026

Internal sync

Jun 18, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT00089661

Title

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer

Sponsor

Amgen

Status

COMPLETED

Phase

PHASE3

Condition raw

Breast Cancer, Low Bone Mineral Density, Osteopenia

Condition normalized

Breast Cancer, Low Bone Mineral Density, Osteopenia

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Placebo, AMG 162 / Denosumab

Target normalized

Placebo, AMG 162 / Denosumab

Interventions

Placebo, AMG 162 / Denosumab

Public preview

Source record

The purpose of this trial is to evaluate AMG 162 in the treatment of bone loss in subjects undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT00089661

Status

COMPLETED

Phase

PHASE3

Sponsor

Amgen

Executive brief

Investment-Ready Snapshot

The purpose of this trial is to evaluate AMG 162 in the treatment of bone loss in subjects undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer.

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedOct 17, 2018

Internal syncJun 18, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00089661

Indication

Breast Cancer

Modality

small molecule

Target

Placebo, AMG 162 / Denosumab

Intervention

Placebo, AMG 162 / Denosumab

Source record